Scholarlink

Background <p>Laryngeal squamous cell carcinoma (LSCC) is a heterogeneous malignant tumor with challenging prognostic assessments. This study aimed to identify DNA methylation markers associated with recurrence risk in LSCC.</p> Methods <p>We analyzed 78 LSCC patients from our hospital, dividing them into recurrence (<i>n</i> = 34) and non-recurrence (<i>n</i> = 44) groups based on disease-free survival (DFS). Reduced representation bisulfite sequencing was performed to identify genome-wide DNA methylation patterns.</p> Results <p>The study identified four differentially methylated regions associated with recurrence risk, located in the promoter regions of <i>RPH3AL</i>, <i>UBE2I</i>, <i>MAPK1</i>, and one distal intergenic region. Based on LASSO logistic regression analysis, we developed a methylation risk signature (MRS) to assess recurrence risk, which achieved an accuracy of 98.2% (54/55) in the training set and 95.7% (22/23) in the validation set. Survival analysis revealed that MRS could significantly stratify DFS (HR = 79.23, <i>P</i> &lt; 0.001) in LSCC patients. No significant correlation was observed between MRS and stage, age, or histological grade in our data.</p> Conclusions <p>This genome-wide DNA methylation analysis provides a promising prediction model for LSCC recurrence risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A recurrence risk prediction model based on DNA methylation in laryngeal squamous cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Jing Bai,
  • Zhiyi Wan,
  • Shoutao Dang,
  • Yong Zhang,
  • Yichuan Qin,
  • Xiangyi Liu

摘要

Background

Laryngeal squamous cell carcinoma (LSCC) is a heterogeneous malignant tumor with challenging prognostic assessments. This study aimed to identify DNA methylation markers associated with recurrence risk in LSCC.

Methods

We analyzed 78 LSCC patients from our hospital, dividing them into recurrence (n = 34) and non-recurrence (n = 44) groups based on disease-free survival (DFS). Reduced representation bisulfite sequencing was performed to identify genome-wide DNA methylation patterns.

Results

The study identified four differentially methylated regions associated with recurrence risk, located in the promoter regions of RPH3AL, UBE2I, MAPK1, and one distal intergenic region. Based on LASSO logistic regression analysis, we developed a methylation risk signature (MRS) to assess recurrence risk, which achieved an accuracy of 98.2% (54/55) in the training set and 95.7% (22/23) in the validation set. Survival analysis revealed that MRS could significantly stratify DFS (HR = 79.23, P < 0.001) in LSCC patients. No significant correlation was observed between MRS and stage, age, or histological grade in our data.

Conclusions

This genome-wide DNA methylation analysis provides a promising prediction model for LSCC recurrence risk.